FLASH SALE - Register in the next 48 hours and save 20% off your GRx+Biosims registration

Speakers Announced

Speakers for GRx+Biosims have been announced and this is one line-up that you won't want to miss.

Learn More
New Report

The 10th edition of the Generic Drug Access & Savings in the United States report.

Read 2018 Report
Skyrocketing Drug Prices Are a Threat to Everyone

Use this infographic to learn how generics and biosimilars are a remedy to sky-high health care costs.

Read Blog
Customize Your GRx+Biosims Experience

Create a customized curriculum with AAM's learning tracks to help further your goals at GRx+Biosims.

View Agenda

Working to leave a positive impact on...

Industry

We promote competition in the pharmaceutical industry by lowering barriers to entry for manufacturers and combatting anti-competitive abuses by some brand drug companies who put profits before patients. Learn More

People

We measure our success as an industry by the lives we impact. We work to protect the low cost of current drugs and to drive down the cost of developing new ones, expanding access to as many people as possible. Learn More

Society

We are a trusted partner and established authority within the pharmaceutical field. We provide accurate, timely data to educate policymakers and promote general public knowledge regarding the positive impact of affordable medicines. Learn More

About Us

The Association for Accessible Medicines, formerly the Generic Pharmaceutical Association, improves access to safe, quality, effective medicine. Better access to medicine is relevant to everybody because, after all, we’re all patients at some point.

Health is the foundation for everything in life. Healthy people are better able to reach their full potential. Generics and biosimilars help more people in more places live healthier and longer.

Recent Updates

Video

Aug 14, 2018 | Erica Klinger

Christine Simmon: GRxBiosims Combines Three Events into One

FDA's Competitive Generic Therapy (CGT) Designation

Aug 8, 2018 | Rachel Schwartz

AAM Statement in Response to FDA's Competitive Generic Therapy (CGT) Designation

Calendar - Pharmaceutical Patent Abuse

Aug 7, 2018 | Erik Komendant

Pharmaceutical Patent Abuse: To Infinity and Beyond!

Video

Aug 3, 2018 | Erica Klinger

AAM CEO Chip Davis Personal Invite to GRx+Biosims 2018

Aug 1, 2018 | Sara Skubikowski

Patients Can See Their Savings

Video

Jul 31, 2018 | Erica Klinger

Christine Simmon Reacts to the Release of FDA's Biosimilars Action Plan